Research across Chronic Obstructive Pulmonary Disease
Related studies from across the Chronic Obstructive Pulmonary Disease family.
Part of Chronic Obstructive Pulmonary Disease
3 published articles · Updated continuously
12 trials tracked for acute exacerbation of chronic obstructive pulmonary disease: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 125 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Management of COPD involves various pharmacological and rehabilitative approaches. Clinical trials evaluated the impact of Roflumilast on exacerbation rates, finding no statistically significant difference in the rate of moderate or severe exacerbations per patient per year (p=0.1634) or those requiring hospitalization/death (p=0.6354). Additionally, there was no significant difference in the rate of exacerbations treated with antibiotics (p=0.0884).
Pharmacological interventions include corticosteroids and bronchodilators; for example, Prednisone was evaluated regarding treatment failure at 90 days 3, and Theophylline ER was associated with changes in St. George Respiratory Questionnaire (SGRQ) scores 4. Antibiotic therapy comparisons between Levofloxacin and Prulifloxacin showed specific counts of therapeutic success at the end of a 10-day cycle 2.
Pulmonary rehabilitation programs, including home-based models, have been evaluated for their impact on quality of life and physical symptoms. Home-based pulmonary rehabilitation was associated with changes in EQ-5D scores 6 and significant improvements in emotional symptoms as measured by the Chronic Respiratory Questionnaire (CRQ) 11.
AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Chronic Obstructive Pulmonary Disease family.